Study Comparing Two Sedation Methods for Awake Fiberoptic Intubation Using Dexmedetomidine or a Placebo with Midazolam and Fentanyl

What this Trial Is About

Researchers are evaluating the effects of different sedation drugs used during awake fiberoptic intubation, a procedure for patients with potentially difficult airways. This observational study compares two sedation protocols involving drugs approved by the FDA for procedural sedation, including midazolam, fentanyl, and either dexmedetomidine or a placebo. The study aims to determine if dexmedetomidine better maintains breathing compared to the standard combination of drugs. Participants will be randomly assigned to one of two groups one receiving dexmedetomidine along with midazolam and fentanyl, and the other receiving a placebo with midazolam and fentanyl. Both groups will also receive lidocaine applied directly or via transtracheal injection to reduce irritation during intubation. Doses of dexmedetomidine will follow recommended guidelines between 0.3 and 0.7 mcgkghour. Standard airway precautions and alternative devices will be available for patient safety. During the procedure, researchers will record oxygen levels, heart and blood pressure stability, and the amount of fentanyl used. Patient discomfort, gagging, and satisfaction with the intubation will also be assessed, including a brief survey 24 hours after surgery. Medical records and observations by anesthesiologists and research staff will provide data to evaluate sedation effectiveness and patient experience throughout the study.

Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation